Nutriband signs commercial development & clinical supply agreement with Kindeva for Aversa Fentanyl patch

NutriBand Inc.

Kindeva to perform commercial process development & supply clinical materials for FDA abuse liability study.
Agreement replaces prior feasibility deal; moves AVERSA Fentanyl toward NDA filing.
AVERSA Fentanyl estimated peak annual US sales $80M-$200M per Health Advances 2022 market analysis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.